Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
archives
»
Monthly Archive
» March 2012
March 2012
Pernix Therapeutics Holdings' Earnings Beat Last Year's by 220%
Pernix Therapeutics Holdings' Earnings Beat Last Year's by 220%
Motley Fool
earnings
Pernix
Don't Get Too Worked Up Over Simcere Pharmaceutical Group's Earnings
Don't Get Too Worked Up Over Simcere Pharmaceutical Group's Earnings
Motley Fool
Simcere
earnings
Pfizer Judge Certifies Class Action Over Celebrex, Bextra
Pfizer Judge Certifies Class Action Over Celebrex, Bextra
Bloomberg
Pfizer
Celebrex
Bextra
Class Action Lawsuit
For Illumina, Roche's Third Offer Not So Charming
For Illumina, Roche's Third Offer Not So Charming
Seeking Alpha
Roche
M&A
Illumina
Panel Recommends More Testing for Obesity Drugs
Panel Recommends More Testing for Obesity Drugs
NY Times, NY
obesity
FDA
advisory panels
Genzyme sends drug for rare cholesterol disorder to FDA
Genzyme sends drug for rare cholesterol disorder to FDA
Bizjournals.com
FDA
Genzyme
Kynamro
Homozygous Familial Hypercholesterolemia
Omeros Corporation Continues To Look Strong
Omeros Corporation Continues To Look Strong
Seeking Alpha
Omeros
MASP-2
PharmacoSurgery
surgery
Roche Breast Cancer Drug Delays Disease Worsening in Study
Roche Breast Cancer Drug Delays Disease Worsening in Study
Bloomberg
Roche
breast cancer
T-DM1
Herceptin
Durect reports Hospira returns rights to Posidur in U.S. and Canada
Durect reports Hospira returns rights to Posidur in U.S. and Canada
Yahoo/Fly on the Wall
Posidur
Canda
Durect Corporation
Hospira
2 Positive Signs for Cubist
2 Positive Signs for Cubist
Motley Fool
Cubist Pharmaceuticals
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »